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759echocardiography, and/or nuclear imaging (3) all
recognize the possibility of regional involvement
from cardiotoxicity. Abnormal regional myocardial
strain assessment—which is more sensitive for iden-
tifying regional functional abnormalities than visual
assessment alone—has been described, particularly
with anthracycline therapy (4). However, none of
these studies has reported a consistent pattern of
regional wall motion abnormalities. Additionally, we
are unaware of publications that have demonstrated a
relationship between a particular regional pattern of
wall motion abnormalities with cardiomyopathy or
heart failure.
In clinical practice, we have not noticed the
speciﬁc pattern of inferolateral wall motion abnor-
mality mentioned by Dr. Drinkovic, although we
have not evaluated this systematically. Nonetheless,
the occurrence of visibly detectable regional wall
abnormalities during cancer chemotherapy may
signify signiﬁcant myocardial injury and may be
associated with a reduction in left ventricular ejec-
tion fraction. Whether management decisions based
on such ﬁndings will improve outcomes such as the
development of heart failure is unknown. Studies
focused on a regional approach are likely to be
limited by the impact of artifact and apparently
random variation of regional strain values, as well
as the known interobserver variation of regional
wall motion assessment. At present, the expert
consensus document on multimodality imaging
evaluation of adult patients during and after ther-
apy proposes changes of global strain to deﬁne
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Limited EvidenceThe review by Smith and Grundy (1) of the American
College of Cardiology/American Heart Association
Cholesterol Treatment Guideline is helpful, but rec-
ommendations for statin dosing are not supported by
robust evidence. Simvastatin is routinely available in
a 16-fold range of strengths (5 to 80 mg) but the
relationship between statin dose and outcomes re-
mains controversial. When allowance is made for the
efﬁcacies of the different statins (2), an audit of
Western Australian pharmacies disclosed a 64-fold
range in statin dose prescribed. Statin dose has
important consequences for individual patient out-
comes: avoidable cardiovascular events with insufﬁ-
cient dose, unnecessary side effects with excessive
dose.
Compared with the reduction in low-density lipo-
protein (LDL) cholesterol with the maximum dose of
atorvastatin, 80 mg daily, the effective dose that
lowers LDL by 50%, the ED50, is about 3 mg (2). A
dose of 20 mg daily is near the top of the dose
response curve and likely to be sufﬁcient for most
patients. The relationship with coronary events
weakens with lower levels of cholesterol (3). The
reduction in mortality seen with only 20 to 40 mg of
simvastatin in the Heart Protection Study was inde-
pendent of the fall in serum cholesterol. Clinicians
should probably avoid unnecessarily high statin
doses that increase side effects without meaningful
additional clinical beneﬁt.
Higher dosing is partly driven by small acute cor-
onary studies, which by 3 months demonstrate only a
marginal beneﬁt. The beneﬁt of statin therapy in
meta-analysis even after 1 year is only one third
of that seen by 5 years (2). Atorvastatin 10 mg
daily, compared with placebo, reduces serum LDL
cholesterol by around 40% (1.8 mmol/l) and after 3
years reduces coronary events upward of 40% (2).
The effects of different doses of a statin on outcome
were best addressed in the TNT (Treating to New
Targets) study, in which increasing the dose of ator-
vastatin 8-fold, from 10 to 80 mg daily, had no impact
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760on mortality and reduced coronary events only a
modest 21% but increased abnormal liver function 6-
fold (4). Extrapolating from the 40% reduction in
coronary events with 10 mg daily of atorvastatin in
meta-analysis and the TNT ﬁndings, 80 mg would be
predicted to reduce coronary events by 47%
compared with placebo, a small additional beneﬁt, at
a price of increased side effects. The additional cor-
onary risk reduction seen with higher dose atorvas-
tatin in the TNT study is arguably redundant given
that a similar additional beneﬁt is seen with any
single antihypertensive drug, or aspirin, which pa-
tients are usually also prescribed.
The risks of statins are underestimated in recent
studies, where statin-intolerant patients were
excluded. Independent audits (5) and earlier ran-
domized clinical trials showed that adverse effects
are relatively common and include fatigue, myop-
athy, liver dysfunction (3), cerebral hemorrhage,
subtle cognitive impairment, neuropathy, renal fail-
ure (5), diabetes mellitus, and cataracts (5). Adverse
effects are dose related (5), usually appear before
cardiovascular beneﬁts are obtained and impact
negatively on quality of life, important given the
lifelong nature of statin therapy.
Statins are clearly indicated in secondary pre-
vention but have not been shown to increase
life expectancy in primary prevention. Serum
cholesterol can be elevated in patients without
coronary disease; atheroma can be difﬁcult to pre-
dict and imaging with computed tomography may
guide statin therapy. Titrating the dose against the
individual’s cholesterol response may not be reliable
given inherent variability of measurement and the
confounding effects of posture and intercurrent
illness. Excessive statin dose increases risks of side
effects and may confer little additional beneﬁt.
Closer attention to weight reduction, smoking, blood
pressure, and glucose probably reduces coronary risk
more effectively and safely.*Simon B. Dimmitt, MBBS, BMedSc(Hons)
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Limited EvidenceOur paper published in the August 12th issue of the
Journal presents 2 points of view (1). The ﬁrst author
(S.C.S., Jr.) reviewed the 2013 American College of
Cardiology/American Heart Association (ACC/AHA)
Guideline, which places priority on statin therapy
on the basis of clinical outcomes conﬁrmed by a
systematic review of randomized controlled trials.
The second author (S.G.) focused on low-density
lipoprotein cholesterol (LDL-C), the primary cause of
atherosclerotic cardiovascular disease (ASCVD).
Dr. Dimmitt and colleagues argue for moderate-
intensity statins anytime statins are indicated. They
question whether high-intensity statins are worth
added efﬁcacy compared with costs and side effects.
Regarding efﬁcacy, recent meta-analysis of second-
ary prevention trials showed that for LDL-C “the
lower, the better” for ASCVD risk reduction (2). This
analysis provides justiﬁcation for high-intensity sta-
tins when they can be given safely for most patients
with established ASCVD. In the TNT (Treat-to-New
Targets) trial, for example, atorvastatin 80 mg was
tolerated as well as atorvastatin 10 mg. In TNT, in-
cremental reduction of ASCVD events of 21% by high-
dose atorvastatin compared with moderate dose
cannot be called “modest.” High-intensity statins
thus seem justiﬁed in most patients with established
ASCVD. Unfortunately, meta-analysis (2) ﬁnds that
the majority of patients treated with high-intensity
statins do not achieve LDL-C in the range where
still greater risk reduction could be achieved. Statins
are excellent drugs but do not always maximize
the potential for risk reduction inherent in LDL-C
lowering therapy. New and efﬁcacious drugs be-
yond statins are needed.
